Back to search

Netherlands· NL-6b0f26dcef28

GHRYVELIN 60 mg granulaat voor orale suspensie in sachet

A macimorelin product containing macimorelineacetaat, registered in Netherlands by Atnahs Pharma Netherlands B.V.. The same ATC class is registered in 12 of our 19 countries.

ATC V04CD06

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedGHRYVELIN 60 mg granulaat voor orale …ATCV04CD06REGISTER NO.NL-6b0f26dcef28PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Macimorelin is registered in 12 of 19 countries.

Countries holding a registration under ATC V04CD06 (macimorelin), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose

Macimorelin · ATC V04CD06

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
MACIMORELINEACETAAT
Manufacturer
Atnahs Pharma Netherlands B.V.
Country
Netherlands (NL)
ATC code
V04CD06
ATC class
Macimorelin
Defined daily dose
35 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/18/1337

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

398 interactions on record for macimorelin.

Graded by severity as the source publishes them — 241 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Macimorelin · interactions on record

398 records

  • 241 severe
  • 154 moderate
  • 3 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Macimorelin in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All macimorelin products

Authorised across Europe · EMA

The same active substance is authorised in 1 EEA country. Names it is sold under:

  • United Kingdom (Northern Ireland) · Macimorelin Atnahs Pharma

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4f63fb31-9739-44d0-a776-404322331260
GET /v1/drugs/4f63fb31-9739-44d0-a776-404322331260?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Granulaat voor orale suspensie",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ghryvelin-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Macimorelin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp122122",
  "excipients": [
    "CROSPOVIDON (E 1202)",
    "LACTOSE 1-WATER",
    "NATRIUMSTEARYLFUMARAAT",
    "SACCHAROIDE NATRIUM X-WATER (E 954)",
    "SILICIUMDIOXIDE (E 551)"
  ],
  "substances": [
    "MACIMORELINEACETAAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2019/01/11",
  "procedure_number": "EMEA/H/C/004660",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/18/1337",
  "additional_monitoring": "N"
}

See everything about macimorelin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.